Antibody-functionalized gold nanoparticles as tumor-targeting radiosensitizers for proton therapy.


Journal

Nanomedicine (London, England)
ISSN: 1748-6963
Titre abrégé: Nanomedicine (Lond)
Pays: England
ID NLM: 101278111

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 25 1 2019
medline: 30 4 2019
entrez: 25 1 2019
Statut: ppublish

Résumé

This study aimed at developing antibody-functionalized gold nanoparticles (AuNPs) to selectively target cancer cells and probing their potential radiosensitizing effects under proton irradiation. AuNPs were conjugated with cetuximab (Ctxb-AuNPs). Ctxb-AuNP uptake was evaluated by transmission electron microscopy and atomic absorption spectroscopy. Radioenhancing effect was assessed using conventional clonogenic assay. Ctxb-AuNPs specifically bound to and accumulated in EGFR-overexpressing A431 cells, compared with EGFR-negative MDA-MB-453 cells. Ctxb-AuNPs enhanced the effect of proton irradiation in A431 cells but not in MDA-MB-453 cells. These data indicate, for the first time, that combining enhanced uptake by specific targeting and radioenhancing effect, using conjugated AuNPs, is a promising strategy to increase cell killing by protontherapy.

Identifiants

pubmed: 30675822
doi: 10.2217/nnm-2018-0161
doi:

Substances chimiques

Antibodies 0
Radiation-Sensitizing Agents 0
Gold 7440-57-5
Cetuximab PQX0D8J21J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

317-333

Auteurs

Sha Li (S)

Research Center for the Physics of Matter & Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Sandra Bouchy (S)

Unité de Recherche en Biologie Cellulaire (URBC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Sebastien Penninckx (S)

Research Center for the Physics of Matter & Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Riccardo Marega (R)

Research Center for the Physics of Matter & Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Ornella Fichera (O)

Research Center for the Physics of Matter & Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Bernard Gallez (B)

Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain, B-1200 Woluwé, Saint Lambert, Belgium.

Olivier Feron (O)

Pole of Pharmacology & Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCL (Université Catholique de Louvain), B-1200 Brussels, Belgium.

Philippe Martinive (P)

Department of Radiotherapy & Oncology, CHU & University of Liège, B-4000 Liège, Belgium.

Anne-Catherine Heuskin (AC)

Research Center for the Physics of Matter & Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Carine Michiels (C)

Unité de Recherche en Biologie Cellulaire (URBC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Stéphane Lucas (S)

Research Center for the Physics of Matter & Radiation (PMR-LARN), Namur Research Institute for Life Sciences (NARILIS), University of Namur, B-5000 Namur, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH